Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

A 17-year-old woman presented with firm, fiercely itching blisters on her fingers and the back of her hand. About 2 weeks beforehand, she had been tattooed with henna while on vacation. In ...

Shortly after we made a diagnosis of bullous pemphigoid in this minipig ... of unusual skin lesions and for differentiation of this dermatosis from the various vesicular viral diseases 7.

This review focuses on the progress which has been achieved in inherited bullous dermatoses.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

bullous diseases, hyperhidrosis, infections, malignancies, and ulcerations. Contact dermatitis represents one-third of the dermatoses in amputees wearing prostheses. All patients who are suspected ...

exfoliative dermatitis and bullous eruptions of the skin, including pemphigus, in which they have often been life saving. 1–4 It is in these conditions, however, largely as a result of the use ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...